MIVACURIUM CHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Mivacurium Chloride patents expire, and when can generic versions of Mivacurium Chloride launch?
Mivacurium Chloride is a drug marketed by Rising and Woodward and is included in two NDAs.
The generic ingredient in MIVACURIUM CHLORIDE is mivacurium chloride. There are two drug master file entries for this compound. Additional details are available on the mivacurium chloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Mivacurium Chloride
A generic version of MIVACURIUM CHLORIDE was approved as mivacurium chloride by WOODWARD on October 12th, 2021.
Summary for MIVACURIUM CHLORIDE
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 53 |
| Clinical Trials: | 2 |
| Patent Applications: | 622 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | MIVACURIUM CHLORIDE at DailyMed |
Recent Clinical Trials for MIVACURIUM CHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Tang-Du Hospital | Phase 2 |
| Jiangsu Nhwa Pharmaceutical Co., Ltd. | Phase 2 |
| Jiangsu Nhwa Pharmaceutical Co., Ltd. | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for MIVACURIUM CHLORIDE
US Patents and Regulatory Information for MIVACURIUM CHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rising | MIVACURIUM CHLORIDE | mivacurium chloride | INJECTABLE;INJECTION | 078562-001 | Apr 30, 2009 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Woodward | MIVACURIUM CHLORIDE | mivacurium chloride | SOLUTION;INTRAVENOUS | 209708-001 | Oct 12, 2021 | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Woodward | MIVACURIUM CHLORIDE | mivacurium chloride | SOLUTION;INTRAVENOUS | 209708-002 | Oct 12, 2021 | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
